Keele, UK, 15 March 2022 – Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue, is pleased to announce that Professor Paul Stoodley will be presenting the results of his in vitro study into the effectiveness of different dual combination antibiotics in killing antibiotic resistant and tolerant persister cells in lawn biofilms of Staphylococcus aureus and Pseudomonas aeruginosa at the American Academy of Orthopaedic Surgeons Annual Meeting (AAOS), being held in Chicago, 22-26 March 2022.
Oral Abstract Session/Presentation title: Killing of antibiotic resistant and tolerant persister cells in Staphylococcus aureus and Pseudomonas aeruginosa agar lawn biofilms with combination antibiotics released from high purity calcium sulphate beads.
Programme Number: 342
Presenting Authors: Kelly Elizabeth Moore1, Anthony Li1, Craig P Delury2, Phillip A Laycock2, Sean Aiken2, Paul Stoodley1
Date & Time: 24 March, 09:05am – 09:10am CST
Biocomposites booth: 818
1 Microbial Infection and Immunity, The Ohio State University
2 Biocomposites Ltd, Keele, United Kingdom
Paul Stoodley, PhD. Director, Campus Microscopy and Imaging Facility (CMIF), Professor, Departments of Microbial Infection and Immunity and Orthopedics, Infectious Diseases Institute, The Ohio State University said: “I am excited to present this research that demonstrates that combining vancomycin and tobramycin or rifampin and meropenem into STIMULAN beads releases a high enough concentration of antibiotic to completely kill cells in lawn biofilms of Staphylococcus aureus and Pseudomonas aeruginosa. The study also demonstrated the importance of sufficient coverage of beads in order to eradicate the biofilm. Antimicrobial resistance is a growing global health challenge and using STIMULAN to get antibiotics to where they are needed at high concentrations for long periods of time is important in killing the entire biofilm and stopping bacteria from mutating.”
Michael Harris, Chief Executive Officer of Biocomposites, added: “Biocomposites is excited to present new STIMULAN data at this distinguished annual meeting as part of our ongoing commitment to share insights and deliver innovative products that help surgeons with their infection management.”
STIMULAN® is the only calcium matrix antibiotic carrier approved to treat bacterial infection in surrounding soft tissue in Canada and for use in bone and soft tissue in EU, UK, and Saudi Arabia. STIMULAN® offers surgeons the flexibility to apply broad spectrum ‘off-the-shelf’ antibiotics at concentrations that will support their patient-specific treatment plans – dramatically improving patient outcomes and redefining standard of care.